BioPartner UK appoints Dr Priya Kalia to Advisory Board

Today, BioPartner UK, the independent, accredited trade organisation that supports UK international trade by promoting and supporting global partnerships, announced the appointment of Dr Priya Kalia, Managing Director of SciTribe Ltd, to its Advisory Board. BioPartner UK’s Advisory Board includes senior investors, executive and non-executive directors, and business development executives. It is focused on driving awareness of global opportunities for small-to-medium enterprises and start-ups, helping to promote membership, and maximising on member services. 

Priya founded SciTribe as a strategic advisory firm focused on positioning, profile-raising, and research for the Science and Technology sectors. Applying over 20 years of combined research and communications experience, SciTribe combines big-picture thinking with specialist insights to develop effective, tailored strategies and multi-channel delivery plans that help organisations succeed in reaching their business and communications objectives. Priya previously worked in medical research and has a BSc(Hons) in Molecular Genetics and Molecular Biology from the University of Toronto, Canada, and a PhD in Regenerative Medicine from UCL. Throughout her career, she has spent time in and worked across different countries, including Canada, UK, Sweden, Finland, and Myanmar.

Lin Bateson, Chief Executive of BioPartner UK, commented:Over the past 14 years, BioPartner has established a significant UK presence at international conferences and created countless networking and business opportunities for UK companies. Priya has been working with our team in readiness to communicate these successes, and to expand our activities. With Priya’s extensive experience in Communications, her presence on our Advisory Board will guarantee that our industry services are aptly showcased, positioning BioPartner as the premier choice for cost savings and international opportunities.” 

Dr Priya Kalia, Managing Director, SciTribe, said: “BioPartner UK has been a pivotal force helping business expand internationally, providing expert knowledge and resources that facilitate travel and attendance at key meetings throughout the year. It is poised for increased growth and success in 2024, and I look forward to assisting the team with its communications strategy to reach its goals, assisting the team to reach the right audiences at the right time and achieve its business development aims.”

For major meetings such as BIO-Europe and BIO-Europe Spring, BioPartner organises a popular UK delegation that signposts potential customers and partners to participating organisations. With strong links to the Department for Business and Trade and other regional hubs and embassies, BioPartner works with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for its members and UK companies travelling with outward delegations. BioPartner also provides access to significant entry fee discounts for key Life Science conferences.
 

More news and updates 

RSSL announces new Biotech Innovation Hub

RSSL, a leading pharmaceutical contract research organisation, has today announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products.

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

 

More within